The biotech sector sees dynamic corporate activity with several key financings, acquisitions, and pipeline adjustments. Twist Bioscience revises fiscal guidance following strong synthetic biology and sequencing revenue growth. MDxHealth acquires Bio-Techne's Exosome Diagnostics business in a transformative $15 million deal. Xoma Royalty Corporation acquires HilleVax and Lava Therapeutics. Notably, Pfizer and Novo Nordisk’s obesity drug pipelines undergo adjustments amid competitive pressures, and BioNTech cuts 90 US jobs reflecting strategic realignment.